Type II raf kinase inhibitors
The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
1. A compound of formula:
or a pharmaceutically acceptable salt or prodrug thereof.
2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt or prodrug thereof, together with a pharmaceutically acceptable carrier.
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof.
4. The pharmaceutical composition of claim 2 comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
5. A method of treating cancer in a subject, wherein the cancer comprises b-raf activated tumors, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt or prodrug thereof.
6. The method of claim 5 , wherein the cancer is melanoma, lung cancer, colon cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, gastric cancer, breast cancer, glioma, glioblastoma, hepatocellular carcinoma, papillary renal carcinoma, head and neck squamous cell carcinoma, leukemia, lymphoma, or myeloma.
7. The method of claim 5 , wherein the cancer is a solid tumor.
8. The method of claim 5 comprising administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.